SPRINT Bibliography
What is SPRINT?
https://pubmed.ncbi.nlm.nih.gov/24902920/
The Systolic Blood Pressure Intervention Trial (SPRINT) is a multicenter, randomized, controlled trial that compares two strategies for treating systolic blood pressure: one focuses on the standard target of <140 mm Hg, and the other included a more intensive target of <120 mm Hg. The primary outcome is the first occurrence of a myocardial infarction (MI), acute coronary syndrome, stroke, heart failure, or cardiovascular disease death. Secondary outcomes include all-cause mortality, decline in kidney function or development of end-stage renal disease, incident dementia, decline in cognitive function, and small-vessel cerebral ischemic disease.
What we learned about heart disease
https://pubmed.ncbi.nlm.nih.gov/26551272
The SPRINT study found that treatment to the systolic blood pressure goal of <120 mm Hg (compared to the <140 mm Hg goal) reduces the risk of major complications or death due to heart problems, including heart attack and heart failure by 30%. In addition, the study showed an overall lower risk of death in the <120 mm Hg group.
What we learned about mild cognitive impairment and dementia
https://pubmed.ncbi.nlm.nih.gov/30688979/
SPRINT is the first clinical trial (the gold standard of research) to demonstrate that something can be done to prevent mild cognitive impairment (MCI) which is often a precursor of dementia. Participants in the <120 mm Hg group had about a 20% reduction in mild cognitive impairment compared to participants in the <140 mm Hg group.
In SPRINT, treating to a systolic blood pressure goal of < 120 mm Hg compared with a goal of < 140 mm Hg did not result in a significant reduction in the risk of probable dementia. Because dementia takes longer to develop, we are continuing with additional phone follow-up of the SPRINT participants.
In SPRINT, treating to a systolic blood pressure goal of < 120 mm Hg compared with a goal of < 140 mm Hg did not result in a significant reduction in the risk of probable dementia. Because dementia takes longer to develop, we are continuing with additional phone follow-up of the SPRINT participants.
Read about other results from SPRINT: